Phase 3 Randomized Study of Intravenous Teplizumab Versus Placebo in Children and Young Adults Aged 1 to 25 with Recently Diagnosed Stage 3 Type 1 Diabetes

What this Trial Is About

Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the effects of teplizumab compared with placebo in children and young adults aged 1 to 25 years with recently diagnosed Stage 3 type 1 diabetes. The study aims to measure changes in blood sugar control and independence from mealtime insulin over 52 weeks while participants continue standard insulin therapy. Participants will be randomly assigned to receive either increasing doses of teplizumab or a matching placebo, both given by intravenous IV infusion. The treatment period lasts 52 weeks, during which participants receive the study drug or placebo by IV infusion. The total study duration for each participant is approximately 84 weeks 19 months, including treatment and follow-up. Throughout the study, participants will undergo regular assessments including blood tests measuring glycated hemoglobin HbA1c, C-peptide levels from meal tolerance tests, and continuous glucose monitoring to track blood sugar levels. Researchers will also monitor insulin use, adverse events, drug concentrations in the blood, and antibody responses. Safety and efficacy are evaluated up to 78 weeks, with multiple visits scheduled across the study period.

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes